The pharmaceutical and biotech industry will benefit from the presumed continuation of Dr. Margaret Hamburg as FDA commissioner in President Barack Obama's second term, GlycoMimetics CEO and Biotechnology Industry Organization board member Rachel King said. "The consistency is positive," said King, who points to advances in the latest Prescription Drug User Fee Act, including the new "breakthrough therapies" designation, improved communication between drugmakers and the agency, and the expansion of accelerated approval.